The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer

Modern Pathology

Volumn 26, Issue 1, 2013, Pages 71-78

  Li, Xiaoxian ^a   Deavers, Michael T ^a   Guo, Ming ^a   Liu, Ping ^a   Gong, Yun ^a   Albarracin, Constance T ^a   Middleton, Lavinia P ^a   Huo, Lei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast; cold ischemia time; estrogen receptor; immunohistochemistry

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURGERY; COHORT ANALYSIS; COLD ISCHEMIA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR BIOPSY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COLD ISCHEMIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SPECIMEN HANDLING; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84871926191     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.135     Document Type: Article

References (32)

1. Fitzgibbons PL, Page DL, Weaver D, et al. Prognosticfactors in breast cancer. College of American PathologistsConsensus Statement 1999. Arch Pathol Lab Med2000;124:966-978
2. Harvey JM, Clark GM, Osborne CK, et al. Estrogenreceptor status by immunohistochemistry is superiorto the ligand-binding assay for predicting response toadjuvant endocrine therapy in breast cancer. J ClinOncol 1999;17:1474-1481 (Pubitemid 29220854)
3. Hammond ME, Hayes DF, Dowsett M, et al. AmericanSociety of Clinical Oncology/College of AmericanPathologists guideline recommendations for immunohistochemicaltesting of estrogen and progesteronereceptors in breast cancer. Arch Pathol Lab Med2010;134:907-922
4. Douglas-Jones AG, Collett N, Morgan JM, et al.Comparison of core oestrogen receptor (ER) assaywith excised tumour: intratumoral distribution of Erinbreast carcinoma. J Clin Pathol 2001;54:951-955 (Pubitemid 34032891)
5. Mann GB, Fahey VD, Feleppa F, et al. Reliance onhormone receptor assays of surgical specimens maycompromise outcome in patients with breast cancerJ Clin Oncol 2005;23:5148-5154 (Pubitemid 46224023)
6. Bai Y, Tolles J, Cheng H, et al. Quantitative assessmentshows loss of antigenic epitopes as a function ofpre-analytic variables. Lab Invest 2011;91:1253-1261
7. Chagpar A, Yen T, Sahin A, et al. Intraoperative marginassessment reduces reexcision rates in patients withductal carcinoma in situ treated with breast-conservingsurgery. Am J Surg 2003;186:371-377 (Pubitemid 38368613)
8. Cabioglu N, Hunt KK, Sahin AA, et al. Role forintraoperative margin assessment in patients undergoingbreast-conserving surgery. Ann Surg Oncol 2007;14:1458-1471 (Pubitemid 46536814)
9. Huo L. A practical approach to grossing breast specimens.Ann Diagn Pathol 2011;15:291-301
10. Von Wasielewski R, Mengel M, Nolte M, et al.Influence of fixation, antibody clones, and signalamplification on steroid receptor analysis. BreastJ 1998;4:33-40 (Pubitemid 28080204)
11. Oyama T, Ishikawa Y, Hayashi M, et al. The effects offixation, processing and evaluation criteria on immunohistochemicaldetection of hormone receptors in breastcancer. Breast Cancer 2007;14:182-188
12. Brearley N, Kumah P, Bell JA, et al. Delay in fixationof invasive breast carcinoma: effect on mitotic count,MIB 1, ER and p53 expression. J Pathol 2001;195:A6(Suppl)
13. Khoury T, Sait S, Hwang H, et al. Delay to formalinfixation effect on breast biomarkers. Mod Pathol 2009;22:1457-1467
14. Qiu J, Kulkarni S, Chandrasekhar R, et al. Effectof delayed formalin fixation on estrogen and progesteronereceptors in breast cancer: a study ofthree different clones. Am J Clin Pathol 2010;134:813-819
15. Apple S, Pucci R, Lowe AC, et al. The effect of delay infixation, different fixatives, and duration of fixation inestrogen and progesterone receptor results in breastcarcinoma. Am J Clin Pathol 2011;135:592-598
16. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect ofcold ischemic time on the immunohistochemicalevaluation of estrogen receptor, progesterone receptor,and HER2 expression in invasive breast carcinoma.Mod Pathol 2012;25:1098-1105
17. Puchtler H, Meloan SN. On the chemistry of formaldehydefixation and its effects on immunohistochemicalreactions. Histochemistry 1985;82:201-204 (Pubitemid 15114056)
18. ArnoldMM, Srivastava S, Fredenburgh J, et al. Effects offixation and tissue processing on immunohistochemicaldemonstration of specific antigens. Biotech Histochem1996;71:224-230 (Pubitemid 26405837)
19. Barnes DM, Harris WH, Smith P, et al. Immunohistochemicaldetermination of oestrogen receptor: comparisonof different methods of assessment of staining andcorrelation with clinical outcome of breast cancerpatients. Br J Cancer 1996;74:1445-1451 (Pubitemid 26370738)
20. Reiner A, Neumeister B, Spona J, et al. Immunocytochemicallocalization of estrogen and progesteronereceptor and prognosis in human primary breastcancer. Cancer Res 1990;50:7057-7061 (Pubitemid 20361113)
21. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogenreceptor analyses. Correlation of biochemical andimmunohistochemical methods using monoclonalantireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721 (Pubitemid 16237466)
22. Goldstein NS, Ferkowicz M, Odish E, et al. Minimumformalin fixation time for consistent estrogen receptorimmunohistochemical staining of invasive breastcarcinoma. Am J Clin Pathol 2003;120:86-92 (Pubitemid 37046374)
23. Tong LC, Nelson N, Tsourigiannis J, et al. The effect ofprolonged fixation on the immunohistochemical evaluationof estrogen receptor, progesterone receptor, andHER2 expression in invasive breast cancer: a prospectivestudy. Am J Surg Pathol 2011;35:545-552
24. Arber DA. Effect of prolonged formalin fixation on theimmunohistochemical reactivity of breast markers.Appl Immunohistochem Mol Morphol 2002;10:183-186 (Pubitemid 34553177)
25. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitativeanalysis of estrogen receptor heterogeneity in breastcancer. Lab Invest 2007;87:662-669 (Pubitemid 46920099)
26. Piper GL, Patel NA, Patel JA, et al. Neoadjuvantchemotherapy for locally advanced breast cancerresults in alterations in preoperative tumor markerstatus. Am Surg 2004;70:1103-1106
27. Neubauer H, Gall C, Vogel U, et al. Changes in tumourbiological markers during primary systemic chemotherapy(PST). Anticancer Res 2008;28:1797-1804 (Pubitemid 351892888)
28. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53,Ki67, and hormone receptors do not change duringneoadjuvant chemotherapy in breast cancer. VirchowsArch 2005;446:489-496 (Pubitemid 40884281)
29. Adams AL, Eltoum I, Krontiras H, et al. The effect ofneoadjuvant chemotherapy on histologic grade, hormonereceptor status, and HER2/neu status in breastcarcinoma. Breast J 2008;14:141-146 (Pubitemid 351341835)
30. Gong Y, Han EY, Guo M, et al. Stability of estrogenreceptor status in breast carcinoma: a comparisonbetween primary and metastatic tumors with regardto disease course and intervening systemic therapy.Cancer 2011;117:705-713
31. Fox CH, Johnson FB, Whiting J, et al. Formaldehydefixation. J Histochem Cytochem 1985;33:845-853
32. Helander KG. Kinetic studies of formaldehyde bindingin tissue. Biotech Histochem 1994;69:177-179 (Pubitemid 24163542)